Serum surfactant protein A as a surrogate biomarker of a negative heart sign among patients with interstitial lung disease

1. Takahashi H, Shiratori M, Kanai A, et al. Monitoring markers of disease activity for interstitial lung

diseases with serum surfactant proteins A and D. Respirology. 2006;11(suppl):S51–S54. doi: 10.1111/j.14401843.2006.00809.x.

2. Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant

protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J

Respir Crit Care Med. 2002;165(3):378–381. doi: 10.1164/ajrccm.165.3.2107134.

3. Takahashi H, Fujishima T, Koba H, et al. Serum surfactant proteins A and D as prognostic factors

in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med.

2000;162(3):1109–1114. doi: 10.1164/ajrccm.162.3.9910080.

4. Ooi GC, Mok MY, Tsang KW, et al. Interstitial lung disease in systemic sclerosis. Acta Radiol.

2003;44(3):258–264. doi: 10.1034/j.1600-0455.2003.00058.x.

5. Line BR, Hunninghake GW, Keogh BA, et al. Gallium-67 scanning to stage the alveolitis of sarcoidosis:

correlation with clinical studies, pulmonary function studies, and bronchoalveolar lavage. Am Rev Respir

Dis. 1981;123(4):440–446. doi: 10.1164/arrd.1981.123.4.440.

6. Crystal RG, Bitterman PB, Rennard SI, et al. Interstitial lung diseases of unknown cause. Disorders

characterized by chronic inflammation of the lower respiratory tract (first of two parts). N Engl J Med.

1984;310(3):154–166. doi: 10.1056/NEJM198401193100304.

7. Liu FY, Shiau YC, Kao A, et al. Comparison of quantitative 99mTc-HMPAO and 67Ga citrate lung scans

in patients with active diffuse infiltrative lung disease. Nucl Med Commun. 2003;24(12):1243–1246.

8. Cooke SG, Davies ER, Goddard PR. Pulmonary uptake in 67-gallium citrate scintigraphy-the ‘negative

heart’ sign. Postgrad Med J. 1989;65(770):885–891. Doi: 10.1136/pgmj.65.770.885.

9. Kobayashi H, Kanoh S, Motoyoshi K. Serum surfactant protein-A, but not surfactant protein-D or

KL-6, can predict preclinical lung damage induced by smoking. Biomarkers. 2008;13(4):385–392. doi:

10.1080/13547500801903651.

10. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory

Society statement: update of the international multidisciplinary classification of the idiopathic interstitial

pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–748. doi: 10.1164/rccm.201308-1483ST.

11. Oka S, Furukawa H, Shimada K, et al. Serum biomarker analysis of collagen disease patients with acuteonset diffuse interstitial lung disease. BMC Immunol. 2013;14:9. doi: 10.1186/1471-2172-14-9.

12. Travis WD, Hunninghake G, King TE Jr, et al. Idiopathic nonspecific interstitial pneumonia: report of an

American Thoracic Society project. Am J Respir Crit Care Med. 2008;177(12):1338–1347. doi: 10.1164/

rccm.200611-1685OC.

13. Jeong YJ, Kim KI, Seo IJ, et al. Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview.

Radiographics. 2007;27(3):617–637. doi: 10.1148/rg.273065051.

14. Lacasse Y, Selman M, Costabel U, et al. Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir

Crit Care Med. 2003;168(8):952–958. doi: 10.1164/rccm.200301-137OC.

15. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American

Thoracic Society/ European Respiratory Society/World Association of Sarcoidosis and other Granulomatous

Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149–173.

16. Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4RD), 2011. Mod Rheumatol. 2012;22(1):21–30. doi: 10.1007/s10165-011-0571-z.

17. Pérez-Dórame R, Mejía M, Mateos-Toledo H, et al. Rheumatoid arthritis-associated interstitial lung disease:

lung inflammation evaluated with high resolution computed tomography scan is correlated to rheumatoid

arthritis disease activity. Reumatol Clin. 2015;11(1):12–16. doi: 10.1016/j.reuma.2014.02.007.

18. Fu Y, Rong M, Zhu P, et al. The circulating fibrocytes are associated with the lung inflammation and

fibrosis of mice with interstitial lung disease. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014;30(8):814–818.

19. Fujiwara A, Kobayashi H, Masuya M, et al. Correlation between circulating fibrocytes, and activity and progression of interstitial lung diseases. Respirology. 2012;17(4):693–698. doi: 10.1111/j.1440-

508

Hisashi Sasaki et al

1843.2012.02167.x.

20. Hara Y, Shinkai M, Kanoh S, et al. Arterial carboxyhemoglobin measurement is useful for evaluating

pulmonary inflammation in subjects with interstitial lung disease. Intern Med. 2017;56(6):621–626. doi:

10.2169/internalmedicine.56.7418.

21. Racanelli AC, Kikkers SA, Choi AMK, et al. Autophagy and inflammation in chronic respiratory disease.

Autophagy. 2018;14(2):221–232. doi: 10.1080/15548627.2017.1389823.

22. Balestro E, Calabrese F, Turato G, et al. Immune inflammation and disease progression in idiopathic

pulmonary fibrosis. PLoS One. 2016;11(5):e0154516. doi: 10.1371/journal.pone.0154516.

23. Kanoh S, Kobayashi H, Motoyoshi K. Exhaled ethane: an in vivo biomarker of lipid peroxidation in

interstitial lung diseases. Chest. 2005;128(4):2387–2392. doi: 10.1378/chest.128.4.2387.

24. Faverio P, Bini F, Vaghi A, et al. Long-term macrolides in diffuse interstitial lung diseases. Eur Respir

Rev. 2017;26(146):pii.170082. doi: 10.1183/16000617.0082-2017.

25. Kinder BW, Brown KK, McCormack F, et al. Serum surfactant protein-A is a strong predictor of early

mortality in idiopathic pulmonary fibrosis. Chest. 2009;135(6):1557–1563. doi: 10.1378/chest.08-2209.

...